US Stock Movements: Palvella surged on October 28—QTORIN Priority Review + Rare Disease New Drug
Bitget异动解读2026/10/28 20:01Palvella October 28th Surge Analysis
Keywords: QTORIN Priority Review, Rare Disease New Drug
On October 28th, the FDA accepted Palvella's new drug application for QTORIN 3.9% anhydrous rapamycin gel for the treatment of microcystic lymphatic malformations and granted it priority review, with a target action date of February 28, 2027. According to the company, all six prespecified efficacy endpoints of the Phase III SELVA study achieved high statistical significance (all p<0.001), and among participants aged 6 years and older who completed efficacy assessment, 95% showed improvement on the primary endpoint.
(Disclaimer: This content is a summary generated by AI technology based on publicly available information, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
